| Name | Title | Contact Details |
|---|
OHCOW is a Windsor, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acuity Healthcare is an employee-owned Long Term Acute Care (LTAC) hospital company, founded in 2001. Acuity is the only company with the flexibility to tailor its services to meet the specific needs of its clients. We understand how LTAC services can, and should work, within today`s "post-acute continuum". This innate flexibility and core understanding of the complexities of the healthcare continuum has enabled Acuity to develop a broad array of services that include: Joint Ventured ownership of its LTAC hospitals with area physicians and local hospitals, full LTAC contract management services, full LTAC contract financial management services and complete LTAC consulting services.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
Season Health is a food as medicine platform that provides clinical nutrition care, meal recommendations, education, and food delivery to people with chronic conditions such as diabetes and kidney disease.